Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Dow
McKesson
McKinsey
AstraZeneca

Last Updated: June 8, 2023

CLINICAL TRIALS PROFILE FOR ESKETAMINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Esketamine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00847418 ↗ Pharmacokinetics and Pharmacodynamics of Nasally Applied Esketamine Completed University Hospital, Basel, Switzerland Phase 1 2009-02-01 The purpose of this study is the determination of blood concentration and the effectiveness of esketamine after nasal application.
NCT01640080 ↗ A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression Completed Janssen Research & Development, LLC Phase 2 2012-06-27 The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
NCT01780259 ↗ A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants Completed Janssen Research & Development, LLC Phase 1 2012-12-01 The primary purpose of the study is to evaluate the pharmacokinetics (what the body does to the medication) of intranasally (through the nose) administered esketamine in healthy participants.
NCT01980303 ↗ A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers Completed Janssen Research & Development, LLC Phase 1 2013-11-01 The purpose of this Phase 1 study is to characterize the pharmacokinetic profile (what the body does to the medication) of esketamine when given by the intranasal route (through the nose) to healthy adult Japanese and Caucasian participants.
NCT01998958 ↗ A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression Completed Janssen Research & Development, LLC Phase 2 2014-01-27 The purpose of this study is to assess the efficacy and dose response of intranasal esketamine (Panel A: 28 mg, 56 mg, and 84 mg and Panel B: 14 mg and 56 mg) compared with placebo in improving depressive symptoms in participants with treatment-resistant depression (TRD).
NCT02060929 ↗ A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device Completed Janssen Research & Development, LLC Phase 1 2013-10-01 The primary purpose of the study is to evaluate the pharmacokinetics (what the body does to the medication) of intranasally (through the nose) administered esketamine using a device with and without a nasal guide in healthy participants.
NCT02094378 ↗ A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects Completed Janssen Research & Development, LLC Phase 1 2014-06-01 The purpose of this study is to assess the cognitive effects associated with administration of intranasal esketamine 84 mg.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Esketamine Hydrochloride

Condition Name

Condition Name for Esketamine Hydrochloride
Intervention Trials
Healthy 14
Esketamine 12
Depression 9
Major Depressive Disorder 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Esketamine Hydrochloride
Intervention Trials
Depression 42
Depressive Disorder 40
Depressive Disorder, Treatment-Resistant 18
Depressive Disorder, Major 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Esketamine Hydrochloride

Trials by Country

Trials by Country for Esketamine Hydrochloride
Location Trials
United States 263
China 41
Belgium 20
Poland 14
Canada 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Esketamine Hydrochloride
Location Trials
California 16
Georgia 14
Maryland 14
Ohio 13
New York 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Esketamine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Esketamine Hydrochloride
Clinical Trial Phase Trials
Phase 4 29
Phase 3 15
Phase 2/Phase 3 3
[disabled in preview] 73
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Esketamine Hydrochloride
Clinical Trial Phase Trials
Not yet recruiting 43
Completed 40
Recruiting 31
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Esketamine Hydrochloride

Sponsor Name

Sponsor Name for Esketamine Hydrochloride
Sponsor Trials
Janssen Research & Development, LLC 34
Peking University First Hospital 5
Yangzhou University 4
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Esketamine Hydrochloride
Sponsor Trials
Other 107
Industry 44
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Merck
Colorcon
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.